Clinical trials
Stem Cell Transplantation clinical trials
Below are recruiting stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 596 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07507760RecruitingPhase 2
Oral decitabine plus ivosidenib for older AML patients
This trial tests a combination of two oral drugs (decitabine and ivosidenib) as a first treatment for older or frail adults with AML that has an IDH1 mutation. The goal is to see if this pill-only regimen is safe and effective without needing intensive chemotherapy.
AveiroAges 18 years+ - NCT07500753Recruiting
Study of a conditioning regimen for older adults with hard-to-treat leukemia or MDS
This trial tests a chemotherapy combination (Clad-LABU) to prepare older patients for a stem cell transplant. It is for people aged 50 or older with relapsed or refractory AML or high-risk MDS.
Suzhou, JiangsuAges 50 years+ - NCT07493161Recruiting
Chemo with targeted therapy for new Ph+ ALL
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07490288Recruiting
Venetoclax, azacitidine, and mitoxantrone for new AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
Tianjin, Tianjin MunicipalityAges 14–100 - NCT07495631Recruiting
Chemo + venetoclax + immunotherapy for adult ALL
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07442513RecruitingPhase 3
Preventing Bleeding in Stem Cell Transplant
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
Hangzhou, ZhejiangAges 18–70 - NCT07441291RecruitingPhase 3
CAR-T vs donor immune cells for residual leukemia after transplant
This study tests whether a therapy using your own immune cells (CAR-T) works better than donor immune cells (DLI) to remove leftover leukemia cells after a stem cell transplant. The goal is to prevent the leukemia from coming back.
Beijing, ChinaAges 3–79 - NCT07436650Recruiting
Laser therapy for mouth sores in children having a bone marrow transplant
This study tests whether a special kind of laser therapy (called high-level laser therapy) can help heal severe mouth sores in children who are having a bone marrow transplant. If your child has painful mouth sores from the transplant, this treatment might reduce pain and speed healing.
Cairo, Cairo GovernorateAges Up to 18 years - NCT06809699RecruitingPhase 1
Stem cell transplant using a partially matched family donor
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
Hangzhou, ChinaAges 18–60 - NCT07425782RecruitingPhase 2
Venetoclax and azacitidine as consolidation for high-risk AML
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
Suzhou, JiangsuAges 18 years+ - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+ - NCT07400328RecruitingPhase 2
Stem cell injection to prevent severe mouth sores in transplant
This trial is testing a single injection called Amimestrocel to prevent severe mouth sores in people getting a stem cell transplant. The study is for adults who are receiving high-dose conditioning with total body irradiation or melphalan, which often cause painful mouth inflammation.
Suzhu, JiangsuAges 18–65 - NCT06830421RecruitingPhase 3
High-dose chemo with stem cell transplant vs. standard therapy for older adults with CNS lymphoma
This study compares a high-dose chemotherapy followed by your own stem cell transplant to standard chemo-immunotherapy for older adults with newly diagnosed primary CNS lymphoma. The goal is to see which approach works better and is safer for people over 70.
Freiburg im Breisgau, Baden-WurttembergAges 65 years+ - NCT06756061RecruitingPhase 2
Ruxolitinib and steroids for chronic graft-versus-host disease
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Seoul, Banpo-daero/Seocho-guAges 19 years+ - NCT07362095RecruitingPhase 1/Phase 2
Luspatercept for anemia after a stem cell transplant
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
Guangzhou, GuangdongAges 18–70 - NCT07359859RecruitingPhase 2
Ruxolitinib to prevent GVHD in stem cell transplant
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Basking Ridge, New JerseyAges 18 years+ - NCT03717623RecruitingPhase 4
Study blood levels of posaconazole in adults
This study looks at how much posaconazole stays in your body while you receive it to prevent fungal infections during chemotherapy or after a stem cell transplant. Your care team will use standard posaconazole treatment and may take extra blood samples to understand its levels.
Parkville, VictoriaAges 18 years+ - NCT07340723RecruitingPhase 2
New treatment study for grade II acute GVHD after transplant
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06548958Recruiting
TBI and chemotherapy before a second stem cell transplant
This trial tests a combination of total body irradiation and two chemotherapy drugs as preparation for a second stem cell transplant in people with blood cancers that relapsed or didn't respond to the first transplant.
Suzhou, JiangsuAges 14–70 - NCT07297303Recruiting
Lung health study after stem cell transplant
This study follows lung health after a stem cell transplant from a donor, to understand and manage chronic graft-versus-host disease (a condition where donor cells attack the body). It may help people who are about to have their first donor transplant.
TaipeiAges 18 years+ - NCT07297173RecruitingPhase 1
Immune cell infusion plus transplant for tough leukemia
This trial tests a new two-step approach for people with hard-to-treat leukemia. First, you get chemotherapy plus an infusion of special immune cells from a partially matched donor, then a stem cell transplant. The goal is to see if this is safe and helps the leukemia go away.
BeijingAges 15 years+ - NCT03667599Recruiting
Home care program after your stem cell transplant
This study tests whether extra home-based medical support after a stem cell transplant can help patients during recovery. If you’re eligible, a trained care team will support you at home so you’re safer and better managed after discharge.
Durham, North CarolinaAges 18–80 - NCT06879847Recruiting
Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Suzhou, JiangsuAges 14–70 - NCT07209501Enrolling by invitation
Aromatherapy for stem cell transplant patients
This trial tests if inhaling essential oils can help patients who are having a stem cell transplant after high-dose chemotherapy. It aims to see if this is a feasible and acceptable way to feel better during treatment.
SingaporeAges 21–99
Hear when a new Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for stem cell transplantation?
- Yes. Clin2 currently lists 596 recruiting stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.